﻿{"id":12637,"date":"2025-10-11T11:13:58","date_gmt":"2025-10-11T04:13:58","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=12637"},"modified":"2025-10-11T11:13:58","modified_gmt":"2025-10-11T04:13:58","slug":"gefitinib","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/gefitinib\/","title":{"rendered":"Gefitinib"},"content":{"rendered":"<p>(Ph. Eur. monograph 2866)<\/p>\n<p>C<sub>22<\/sub>H<sub>24<\/sub>ClFN<sub>4<\/sub>O<sub>3<\/sub>\u00a0 \u00a0446.9\u00a0 \u00a0 184475-35-2<\/p>\n<p><strong>Action and use<\/strong><\/p>\n<p>Cytotoxic.<\/p>\n<h2>DEFINITION<\/h2>\n<p>N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine.<\/p>\n<h3>Content<\/h3>\n<p>98.0 per cent to 102.0 per cent (anhydrous substance).<\/p>\n<h2>CHARACTERS<\/h2>\n<h3>Appearance<\/h3>\n<p>White or almost white, crystalline powder.<\/p>\n<h3>Solubility<\/h3>\n<p>Practically insoluble in water, slightly soluble in anhydrous ethanol, practically insoluble in heptane.<\/p>\n<h2>IDENTIFICATION<\/h2>\n<p>Infrared absorption spectrophotometry (2.2.24).<\/p>\n<p>Comparison gefitinib CRS.<\/p>\n<h2>TESTS<\/h2>\n<h3>Related substances<\/h3>\n<p>Liquid chromatography (2.2.29).<\/p>\n<p>Solvent mixture acetonitrile R, 0.2 per cent V\/V solution of trifluoroacetic acid R (40:60 V\/V).<\/p>\n<p>Test solution: Dissolve 35.0 mg of the substance to be examined in 85 mL of the solvent mixture, with the aid of ultrasound, and dilute to 100.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (a): Dissolve 35.0 mg of gefitinib CRS in 85 mL of the solvent mixture, with the aid of ultrasound, and dilute to 100.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (b): Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (c): Dissolve the contents of a vial of gefitinib for system suitability CRS (containing impurity B) in 1.0 mL of the solvent mixture with the aid of ultrasound.<\/p>\n<p>Column:<\/p>\n<p>\u2014 size: l = 0.10 m, \u00d8 = 3 mm;<\/p>\n<p>\u2014 stationary phase: base-deactivated end-capped octadecylsilyl silica gel for chromatography R (3 \u03bcm);<\/p>\n<p>\u2014 temperature: 60 \u00b0C.<\/p>\n<p>Mobile phase acetonitrile R, 9.68 g\/L solution of ammonium acetate R (38:62 V\/V).<\/p>\n<p>Flow rate 0.9 mL\/min.<\/p>\n<p>Detection Spectrophotometer at 247 nm.<\/p>\n<p>Injection 5 \u03bcL of the test solution and reference solutions (b) and (c).<\/p>\n<p>Run time 5 times the retention time of gefitinib.<\/p>\n<p>Identification of impurities: Use the chromatogram supplied with gefitinib for system suitability CRS and the chromatogram obtained with reference solution (c) to identify the peak due to impurity B.<\/p>\n<p>Relative retention: With reference to gefitinib (retention time = about 5.5 min): impurity B = about 1.3.<\/p>\n<p>System suitability Reference solution (c):<\/p>\n<p>\u2014 resolution: minimum 3.0 between the peaks due to gefitinib and impurity B.<\/p>\n<p>Calculation of percentage contents:<\/p>\n<p>\u2014 for each impurity, use the concentration of gefitinib in reference solution (b).<\/p>\n<p>Limits:<\/p>\n<p>\u2014 impurity B: maximum 0.2 per cent;<\/p>\n<p>\u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n<p>\u2014 total: maximum 0.4 per cent;<\/p>\n<p>\u2014 reporting threshold: 0.05 per cent.<\/p>\n<h4>Water (2.5.32)<\/h4>\n<p>Maximum 0.5 per cent, determined on 0.100 g by direct sample introduction.<\/p>\n<h4>Sulfated ash (2.4.14)<\/h4>\n<p>Maximum 0.2 per cent, determined on 1.0 g in a platinum crucible.<\/p>\n<h2>ASSAY<\/h2>\n<p>Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.<\/p>\n<p>Injection Test solution and reference solution (a).<\/p>\n<p>Calculate the percentage content of C<sub>22<\/sub>H<sub>24<\/sub>ClFN<sub>4<\/sub>O<sub>3<\/sub> taking into account the assigned content of gefitinib CRS.<\/p>\n<h2>IMPURITIES<\/h2>\n<p>Specified impurities B.<\/p>\n<p>Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-12638\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/1-133-300x163.jpg\" alt=\"Gefitinib-1\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/1-133-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/1-133-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/1-133-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/1-133.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>A. 7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4(3H)-one,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-12639\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-132-300x163.jpg\" alt=\"Gefitinib-2\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-132-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-132-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-132-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-132.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>B. N-(4-chloro-3-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Ph. Eur. monograph 2866) C22H24ClFN4O3\u00a0 \u00a0446.9\u00a0 \u00a0 184475-35-2 Action and use Cytotoxic. DEFINITION N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine. Content 98.0 per cent to 102.0 per cent (anhydrous substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Practically insoluble in water, slightly soluble in anhydrous ethanol, practically insoluble in heptane. IDENTIFICATION Infrared absorption spectrophotometry (2.2.24). Comparison gefitinib CRS. TESTS&#8230;<\/p>\n","protected":false},"author":3,"featured_media":12640,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-12637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=12637"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12637\/revisions"}],"predecessor-version":[{"id":12648,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12637\/revisions\/12648"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/12640"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=12637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=12637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=12637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}